1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Canada Pharmaceuticals and Healthcare Report Q1 2017

Canada Pharmaceuticals and Healthcare Report Q1 2017

  • November 2016
  • -
  • Business Monitor International
  • -
  • 88 pages

Includes 3 FREE quarterly updates


BMI View:

Canada’s strong publicly funded health care system and stable political environment supply an attractive base for drug companies. We forecast steady market growth; pricing and reimbursement pressures represent the main headwinds.

Headline Expenditure Projections



- Pharmaceuticals: CAD25.07bn (USD19.61bn) in 2015 to CAD25.83bn (USD19.87bn) in 2016; +3.0% in local currency terms and +1.3% in US dollar terms. Forecast unchanged from previous quarter.

- Healthcare: CAD209.95bn (USD164.22bn) in 2015 to CAD214.85bn (USD165.27bn) in 2016; +2.3% in local currency terms and +0.6% in US dollar terms. Forecast unchanged from previous quarter. Risk/Reward Index In Q117 Canada’s Risk/Rewards Index (RRI) score is an improved 73.8 compared with 71.4 in the previous quarter. Despite the upgrade, Canada retains its position as the second-most attractive market in the Americas region, some way behind the US. The Canadian population continues to show signs of relatively robust expansion when compared to its developed nation peers. Its pensionable population is also high, denoting a greater demand for medication. However, Canada’s score is partially offset by cost containment measures and shortcomings in its intellectual property environment.

Table Of Contents

Canada Pharmaceuticals and Healthcare Report Q1 2017
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Canada 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Canada 2012-2020) 13
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Canada 2012-2020) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Canada 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Canada 2012-2020) 16
Prescription Drug Market Forecast 17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Canada 2012-2020) 18
Patented Drug Market Forecast 19
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Canada 2012-2020) 21
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Canada 2012-2020) 24
OTC Medicine Market Forecast 25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Canada 2012-2020) 26
Pharmaceutical Trade Forecast 27
Table: Pharmaceutical Trade Data And Forecasts (Canada 2014-2020) 28
Table: Pharmaceutical Trade Data And Forecasts local currency (Canada 2014-2020) 29
Industry Risk Reward Index 30
Americas Risk/Reward Index 30
Canada Risk/Reward Index 35
Rewards 35
Risks 35
Regulatory Review 37
Intellectual Property Issues 41
Pricing Regime 43
Reimbursement Regime 44
Market Overview 47
Healthcare Sector 47
Table: Healthcare Resources (Canada 2010-2015) 51
Table: Healthcare Personnel (Canada 2010-2015) 51
Table: Healthcare Activity (Canada 2010-2015) 52
Research and Development 52
Clinical Trials 54
Epidemiology 55
Competitive Landscape 58
Research-Based Industry 58
Table: Multinational Market Activity 61
Pharmaceutical Retail Sector 62
Company Profile 63
Apotex 63
GlaxoSmithKline 66
Merck 68
Novartis 70
Valeant 72
Demographic Forecast 77
Demographic Outlook 77
Table: Population Headline Indicators (Canada 1990-2025) 78
Table: Key Population Ratios (Canada 1990-2025) 78
Table: Urban/Rural Population and Life Expectancy (Canada 1990-2025) 79
Table: Population By Age Group (Canada 1990-2025) 79
Table: Population By Age Group % (Canada 1990-2025) 80
Glossary 82
Methodology 84
Pharmaceutical Expenditure Forecast Model 84
Healthcare Expenditure Forecast Model 84
Notes On Methodology 85
Risk/Reward Index Methodology 86
Index Overview 87
Table: Pharmaceutical Risk/Reward Index Indicators 87
Indicator Weightings 88

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.